MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Alcon Inc

Fermé

SecteurSoins de santé

92.5 -0.03

Résumé

Variation du prix de l'action

24h

Actuel

Min

91.56

Max

92.68

Chiffres clés

By Trading Economics

Revenu

21M

284M

Ventes

48M

2.5B

P/E

Moyenne du Secteur

46.307

63.778

BPA

0.72

Rendement du dividende

0.28

Marge bénéficiaire

11.351

Employés

25,599

EBITDA

56M

397M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+15.91% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.28%

2.39%

Prochains Résultats

13 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

5.9B

47B

Ouverture précédente

92.53

Clôture précédente

92.5

Sentiment de l'Actualité

By Acuity

50%

50%

180 / 386 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Alcon Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 mars 2025, 21:22 UTC

Acquisitions, Fusions, Rachats

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24 mars 2025, 12:36 UTC

Acquisitions, Fusions, Rachats

Alcon to Buy Lensar in Deal Worth Up to $430 Million

12 nov. 2024, 18:48 UTC

Résultats
Principaux Mouvements du Marché

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

26 mars 2025, 21:55 UTC

Market Talk
Acquisitions, Fusions, Rachats

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mars 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mars 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mars 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mars 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26 mars 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26 mars 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26 mars 2025, 20:30 UTC

Acquisitions, Fusions, Rachats

Alcon Acquires Majority Interest in Aurion Biotech

24 mars 2025, 12:21 UTC

Acquisitions, Fusions, Rachats

Alcon to Buy Lensar in Deal Worth Up to $430M

24 mars 2025, 12:05 UTC

Acquisitions, Fusions, Rachats

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24 mars 2025, 12:05 UTC

Acquisitions, Fusions, Rachats

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24 mars 2025, 12:04 UTC

Acquisitions, Fusions, Rachats

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24 mars 2025, 12:04 UTC

Acquisitions, Fusions, Rachats

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24 mars 2025, 12:03 UTC

Acquisitions, Fusions, Rachats

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24 mars 2025, 12:03 UTC

Acquisitions, Fusions, Rachats

Alcon Agrees to Acquire LENSAR >ALC

24 mars 2025, 12:00 UTC

Acquisitions, Fusions, Rachats

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25 févr. 2025, 21:33 UTC

Résultats

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25 févr. 2025, 21:33 UTC

Résultats

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25 févr. 2025, 21:32 UTC

Résultats

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25 févr. 2025, 21:31 UTC

Résultats

Alcon 4Q EPS 57c >ALC.EB

25 févr. 2025, 21:31 UTC

Résultats

Alcon 4Q Rev $2.5B >ALC.EB

17 déc. 2024, 15:05 UTC

Market Talk

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

12 nov. 2024, 17:38 UTC

Résultats

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

12 nov. 2024, 17:38 UTC

Résultats

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

12 nov. 2024, 17:37 UTC

Résultats

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

12 nov. 2024, 17:36 UTC

Résultats

Alcon 3Q Core Operating Margin 20.6% >ALC

12 nov. 2024, 17:36 UTC

Résultats

Alcon 3Q Sales $2.43B >ALC

Comparaison

Variation de prix

Alcon Inc prévision

Objectif de Prix

By TipRanks

15.91% hausse

Prévisions sur 12 Mois

Moyen 107.45 USD  15.91%

Haut 120 USD

Bas 90 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

18

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

90.87 / 92.61Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

180 / 386Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.